Financings in Brief: Genelabs Technologies
This article was originally published in The Gray Sheet
Genelabs Technologies: Calls for warrants issuable in connection with its $20 mil. private placement financing announced in August ("The Gray Sheet" Sept. 4, 1995, p. 8). The warrants, issued to purchase an aggregate of 3.2 mil. shares of common stock at $3.39 per share, are callable "due to the trading prices of the company's common stock over the preceding thirty trading days," Genelabs says. The warrants will expire on March 6...
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.